Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This study will investigate the clinical efficacy, safety, pharmacokinetics (PK) and
pharmacodynamics (PD) of ACZ885, administered intravenously and subcutaneously to patients
with NALP3 mutations whose clinical symptoms are either untreated or insufficiently treated
and require medical intervention.